Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

330
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
330
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

7.4K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

722
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
722
Principles of Drug Action01:24

Principles of Drug Action

6.6K
Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
6.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of injectable ibuprofen and resveratrol co-loaded mesoporous silica nanoparticle-based hydrogels for sustained delivery in osteoarthritis management.

Journal of pharmaceutical sciences·2026
Same author

Khamira Gaozaban Sada, a Low-Cost Unani Preparation, Alleviates Isoproterenol and L-NAME-Induced Augmented Cardiac Workload.

Current pharmaceutical design·2026
Same author

Intrinsic Superconducting Diode Effect Enhancement in FeSeTe by Increased Flux Pinning.

ACS applied materials & interfaces·2026
Same author

Signature of Quantum Phase Slips in a Layered Quasi-One-Dimensional Nb<sub>2</sub>PdS<sub>5</sub> Superconductor.

ACS nanoscience Au·2026
Same author

Recent advances of microbial medicine to prevent and treat cardiovascular disease.

Progress in molecular biology and translational science·2026
Same author

Molecular insights into the antimicrobial and cardiometabolic functions of Lactobacillus crispatus isolated from the reproductive tract microbiota of Indian women.

Journal of biomedical science·2026

Related Experiment Video

Updated: Sep 11, 2025

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

342

Future potential therapeutics to treat MASH.

Shriram Mahajan1, Malladi Navya1, Sanjay K Banerjee1

  • 1Department of Biotechnology, National Institute of Pharmaceutical Education and Research, Guwahati 781101 Assam, India.

Drug Discovery Today
|August 13, 2025
PubMed
Summary

Metabolic dysfunction-associated steatohepatitis (MASH) is a growing liver disease with limited treatments. This review explores new therapies targeting key pathways and novel approaches like gene therapy, offering hope for better MASH management.

More Related Videos

A Simple Alternative to Stereotactic Injection for Brain Specific Knockdown of miRNA
06:53

A Simple Alternative to Stereotactic Injection for Brain Specific Knockdown of miRNA

Published on: December 26, 2015

12.8K
Subcellular Fractionation for ERK Activation Upon Mitochondrial-derived Peptide Treatment
07:55

Subcellular Fractionation for ERK Activation Upon Mitochondrial-derived Peptide Treatment

Published on: September 25, 2017

7.9K

Related Experiment Videos

Last Updated: Sep 11, 2025

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

342
A Simple Alternative to Stereotactic Injection for Brain Specific Knockdown of miRNA
06:53

A Simple Alternative to Stereotactic Injection for Brain Specific Knockdown of miRNA

Published on: December 26, 2015

12.8K
Subcellular Fractionation for ERK Activation Upon Mitochondrial-derived Peptide Treatment
07:55

Subcellular Fractionation for ERK Activation Upon Mitochondrial-derived Peptide Treatment

Published on: September 25, 2017

7.9K

Area of Science:

  • Hepatology
  • Metabolic Disorders
  • Pharmacology

Background:

  • Metabolic dysfunction-associated steatohepatitis (MASH) is a severe form of Metabolic-associated steatotic liver disease (MASLD).
  • MASH is linked to obesity, type 2 diabetes, and cardiovascular issues, presenting a global health concern.
  • Current therapeutic options for MASH are insufficient, necessitating the development of new treatments.

Purpose of the Study:

  • To review emerging therapeutic strategies for MASH.
  • To highlight novel approaches and ongoing research in MASH treatment.
  • To discuss the potential of targeting key MASH pathogenesis pathways.

Main Methods:

  • Review of current literature on MASH pathogenesis and therapeutic targets.
  • Identification of emerging drug classes and novel treatment modalities.
  • Analysis of ongoing clinical trials and mechanistic insights.

Main Results:

  • Emerging therapies target key pathways including THR-β, FXR, PPAR, GLP-1RA, FGF21, and SGLT2.
  • Novel approaches such as gene therapy (siRNA), probiotics, fecal microbiota transplantation, and stem cell therapy show promise.
  • Understanding of fibrosis, inflammation, and lipid metabolism is advancing treatment strategies.

Conclusions:

  • Targeted and multi-modal therapies offer potential for MASH treatment.
  • Gene therapy, microbiome modulation, and cell-based therapies represent promising avenues.
  • Further research on safety, efficacy, and diagnostics is crucial for advancing MASH management.